China SXT Pharmaceuticals (NASDAQ:SXTC) Announces Quarterly Earnings Results

China SXT Pharmaceuticals (NASDAQ:SXTC) issued its earnings results on Wednesday. The company reported ($0.07) earnings per share for the quarter, reports. The business had revenue of $0.26 million for the quarter.

China SXT Pharmaceuticals Stock Up 16.6%

SXTC opened at $2.46 on Thursday. The business’s 50 day moving average is $1.91 and its 200-day moving average is $36.23. China SXT Pharmaceuticals has a twelve month low of $1.25 and a twelve month high of $1,046.98.

Institutional Trading of China SXT Pharmaceuticals

Several large investors have recently added to or reduced their stakes in SXTC. Virtu Financial LLC raised its stake in China SXT Pharmaceuticals by 107.5% during the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after acquiring an additional 15,013 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of China SXT Pharmaceuticals in the 4th quarter worth $36,000. Finally, Citadel Advisors LLC acquired a new stake in shares of China SXT Pharmaceuticals in the third quarter valued at $78,000. 5.02% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut China SXT Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research note on Thursday, June 25th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, China SXT Pharmaceuticals presently has an average rating of “Sell”.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.